article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

Globally, the first rituximab biosimilar, Dr Reddy’s Laboratories’ Reditux, was approved in India in 2007. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.

Sales 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

Lucentis was first approved in the US in 2007 for wet AMD and grew quickly thereafter as additional indications were approved. Roche has US marketing rights to the drug, and booked $1.3 billion in sales from it in 2021, while Novartis made $2.2

FDA 59
article thumbnail

Digitalising HPLC methods: the path to interoperability

European Pharmaceutical Review

Pre-competitive collaboration in this space benefits everyone because whether you are a biopharmaceutical company, vendor, publisher or equipment manufacturer, you are invested in ensuring the research ecosystem works seamlessly and drives new breakthroughs. What is your vision for the lab of the future?

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug

pharmaphorum

The substance patent expired in 2007. ” “Given the importance of this issue to patients, payors (including the federal government), and prescription-drug competition, this court should grant review,” it adds. The post Teva asks SCOTUS to overturn “skinny label” verdict on GSK drug appeared first on.

article thumbnail

Effective Pharma Ad Types & Stats

Pharma Marketing Network

With the increase in competition, it has become essential for pharmaceutical companies to find the most effective methods of advertisement to reach their target audience. ” New England Journal of Medicine, 2007. Pharmaceutical advertising is a crucial aspect of promoting and marketing drugs to the public. ” U.S.

Pharma 52